Abbott Labs: Genworth Financial’s Heaviest Healthcare Stock Position in Q3

Wall St. Watchdog reveals information regarding Genworth Financial’s top holdings in the Healthcare sector for the quarter ending September 30th, 2011. The firm held 20 stocks in the Healthcare sector at the end of the quarter with an aggregate market value of $43.452 million.

  • Abbott Laboratories (NYSE:ABT): On 06/30/2011, Genworth Financial reported holding 178,364 shares with a market value of $9,385,513. This comprised 0.46% of the total portfolio. On 09/30/2011, Genworth Financial reported holding 164,440 shares with a market value of $8,409,461. This comprised 0.32% of the total portfolio. The net change in shares for this position over the two quarters is -13,924. About Company: Abbott Laboratories discovers, develops, manufactures, and sells a broad and diversified line of health care products and services. The Company’s products include pharmaceuticals, nutritional, diagnostics, and vascular products. Abbott markets its products worldwide through affiliates and distributors.
  • Baxter International Inc. (NYSE:BAX): On 06/30/2011, Genworth Financial reported holding 105,132 shares with a market value of $6,275,329. This comprised 0.31% of the total portfolio. On 09/30/2011, Genworth Financial reported holding 96,422 shares with a market value of $5,413,131. This comprised 0.21% of the total portfolio. The net change in shares for this position over the two quarters is -8,710. About Company: Baxter International Inc. develops, manufactures, and markets products and technologies related to hemophilia, immune disorders, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions. The Company’s products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices, and research laboratories.
  • Novartis Ag (NYSE:NVS): On 06/30/2011, Genworth Financial reported holding 102,290 shares with a market value of $6,250,942. This comprised 0.31% of the total portfolio. On 09/30/2011, Genworth Financial reported holding 92,565 shares with a market value of $5,162,350. This comprised 0.2% of the total portfolio. The net change in shares for this position over the two quarters is -9,725. About Company: Novartis AG manufactures pharmaceutical and consumer healthcare products. The Company produces pharmaceuticals for cardiovascular, respiratory and infectious diseases; oncology, neuroscience, transplantation, dermatology, gastrointestinal and urinary conditions, and arthritis; vaccines and diagnostics; vision, and animal health products.
  • Covidien Plc (NYSE:COV): On 06/30/2011, Genworth Financial reported holding 98,962 shares with a market value of $5,267,747. This comprised 0.26% of the total portfolio. On 09/30/2011, Genworth Financial reported holding 91,888 shares with a market value of $4,052,261. This comprised 0.16% of the total portfolio. The net change in shares for this position over the two quarters is -7,074. About Company: Covidien PLC is a global healthcare products company. The Company develops, manufactures and distributes a diverse range of medical devices and supplies, diagnostics imaging agents, pharmaceuticals and other healthcare products for use in clinical and home settings.
  • Life Technologies Corporation (NASDAQ:LIFE): On 06/30/2011, Genworth Financial reported holding 101,551 shares with a market value of $5,287,761. This comprised 0.26% of the total portfolio. On 09/30/2011, Genworth Financial reported holding 94,256 shares with a market value of $3,622,258. This comprised 0.14% of the total portfolio. The net change in shares for this position over the two quarters is -7,295. About Company: Life Technologies Corporation develops biotechnology tools used by researchers. The Company offers a broad range of products and services, including systems, instruments, reagents, and custom services. Life’s portfolio of products includes technologies for capillary electrophoresis based sequencing, sequencing, mass spectrometry sample preparation, and cell culture.
  • Pfizer Inc. (NYSE:PFE): On 06/30/2011, Genworth Financial reported holding 220,342 shares with a market value of $4,539,045. This comprised 0.22% of the total portfolio. On 09/30/2011, Genworth Financial reported holding 201,320 shares with a market value of $3,559,338. This comprised 0.14% of the total portfolio. The net change in shares for this position over the two quarters is -19,022. About Company: Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company’s products include prescription pharmaceuticals, non-prescription self-medications, and animal health products such as anti-infective medicines and vaccines.
  • Merck & Co. Inc. (NYSE:MRK): On 06/30/2011, Genworth Financial reported holding 775 shares with a market value of $27,350. This comprised 0% of the total portfolio. On 09/30/2011, Genworth Financial reported holding 107,808 shares with a market value of $3,525,322. This comprised 0.14% of the total portfolio. The net change in shares for this position over the two quarters is 107,033. About Company: Merck & Co., Inc. is a global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of human and animal health products. Merck’s products include a treatment for elevated cholesterol, a treatment for male pattern hair loss, a preventive treatment for osteoporosis, a treatment for hypertension, and a treatment for allergic rhinitis.
  • Perrigo Co. (NASDAQ:PRGO): On 06/30/2011, Genworth Financial reported holding 30,709 shares with a market value of $2,698,400. This comprised 0.13% of the total portfolio. On 09/30/2011, Genworth Financial reported holding 27,907 shares with a market value of $2,710,049. This comprised 0.1% of the total portfolio. The net change in shares for this position over the two quarters is -2,802. About Company: Perrigo Company manufactures store brand over-the-counter pharmaceutical products and also manufactures store brand nutritional products. The Company’s customers include major national and regional retail drug, supermarket, and mass merchandise chains such as Albertson’s, CVS, and Target, and major wholesalers such as Super Valu and McKesson.
  • Gilead Sciences Inc. (NASDAQ:GILD): On 06/30/2011, Genworth Financial reported holding 55,549 shares with a market value of $2,300,284. This comprised 0.11% of the total portfolio. On 09/30/2011, Genworth Financial reported holding 51,996 shares with a market value of $2,017,445. This comprised 0.08% of the total portfolio. The net change in shares for this position over the two quarters is -3,553. About Company: Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. The Company’s primary arees of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions.
  • Novo Nordisk A/s (NYSE:NVO): On 06/30/2011, Genworth Financial reported holding 20,087 shares with a market value of $2,516,499. This comprised 0.12% of the total portfolio. On 09/30/2011, Genworth Financial reported holding 18,137 shares with a market value of $1,804,994. This comprised 0.07% of the total portfolio. The net change in shares for this position over the two quarters is -1,950. About Company: Novo Nordisk A/S develops, produces, and markets pharmaceutical products. The Company focuses on diabetes care and offers insulin delivery systems and other diabetes products. Novo Nordisk also works in areas such as haemostatis management, growth disorders, and hormone replacement therapy. The Company offers educational and training materials. Novo Nordisk markets worldwide.

(Note: Data regarding Genworth Financial’s stock holdings are sourced from whalewisdom.com. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>